Surufatinib

Generic Name: Surufatinib

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₂₄H_₂₈N_₆O_₃S

CAS Number: 1308672-74-3

Unique Ingredient Identifier: B2K5L1L8S9

Background: Surufatinib is under investigation in clinical trial NCT02588170 (Phase III Study of Surufatinib in Treating Advanced Extrapancreatic Neuroendocrine Tumors).

Indication: 单药用于治疗无法手术切除的局部晚期或转移性、进展期非功能性、分化良好（G1、G2）的胰腺和非胰腺来源的神经内分泌瘤（pNETs）。

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Pamiparib Plus Surufatinib in Patients With Platinum-resistant Ovarian Cancer

Phase 1

Recruiting

Conditions: Ovarian Cancer
Primary Peritoneal Cancer
Ovarian Carcinoma
Fallopian Tube Carcinosarcoma
Platinum-resistant Ovarian Cancer

Interventions: Drug: Pamiparib
Drug: Surufatinib

First Posted Date: 2022-08-10

Last Posted Date: 2023-04-11

Lead Sponsor: Sun Yat-sen University

Target Recruit Count: 38

Registration Number: NCT05494580

Locations: 🇨🇳
Sun Yat-sen University Cancer Cetntre, Guangzhou, China

Surufatinib Combined With Sintilimab and AG in First-line Therapy of Patients With Locally Advanced or Metastatic Pancreatic Cancer

Phase 2

Recruiting

Conditions: Pancreatic Neoplasms

Interventions: Drug: Surufatinib
Drug: Sintilimab
Drug: AG

First Posted Date: 2022-08-01

Last Posted Date: 2023-08-09

Lead Sponsor: Sun Yat-sen University

Target Recruit Count: 32

Registration Number: NCT05481476

Locations: 🇨🇳
Cancer center of SunYat-sen University, Guangzhou, Guangdong, China

Surufatinib Combined With TAS-102 in Third-line and Later-line Therapy of Patients With Advanced Pancreatic Cancer

Phase 2

Recruiting

Conditions: Pancreatic Neoplasms

Interventions: Drug: Surufatinib
Drug: TAS-102

First Posted Date: 2022-08-01

Last Posted Date: 2023-11-13

Lead Sponsor: Sun Yat-sen University

Target Recruit Count: 20

Registration Number: NCT05481463

Locations: 🇨🇳
Cancer center of SunYat-sen University, Guangzhou, Guangdong, China

Surufatinib and Sintilimab in Combination With Capecitabine for Metastatic Adenocarcinoma of Small Intestine or Appendix Carcinoma

Phase 2

Recruiting

Conditions: Adenocarcinoma of Small Intestine
Metastatic
Appendix Carcinoma

Interventions: Drug: Surufatinib
Drug: Sintilimab
Drug: Capecitabine

First Posted Date: 2022-07-25

Last Posted Date: 2023-02-28

Lead Sponsor: Sun Yat-sen University

Target Recruit Count: 36

Registration Number: NCT05472948

Locations: 🇨🇳
The Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China

Surufatinib Alone or Combined With Anti-PD-1 mAb in the Treatment of Advanced Hepatocellular Carcinoma

Phase 2

Recruiting

Conditions: Hepatocellular Carcinoma; Targeted Therapy; Progression-free Survival

Interventions: Drug: Surufatinib

First Posted Date: 2022-03-16

Last Posted Date: 2022-03-16

Lead Sponsor: Zhongnan Hospital

Target Recruit Count: 45

Registration Number: NCT05282433

Locations: 🇨🇳
Zhongnan Hopital of Wuhan University, Wuhan, Hubei, China

Surufatinib in Advanced Hepatocellular Carcinoma Based on Single-cell Sequencing of Tumor Samples

Phase 2

Conditions: Hepatocellular Carcinoma

Interventions: Drug: Surufatinib

First Posted Date: 2021-12-29

Last Posted Date: 2022-04-14

Lead Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Target Recruit Count: 6

Registration Number: NCT05171439

Locations: 🇨🇳
Nanjing Drum tower hospital, Nanjing, Jiangsu, China

Sintilimab Combined With IBI310 and Surufatinib for the Treatment of G3-NET and NEC

Phase 2

Recruiting

Conditions: Neuroendocrine Neoplasm

Interventions: Drug: Sintilimab
Drug: IBI310
Drug: Surufatinib

First Posted Date: 2021-12-21

Last Posted Date: 2021-12-21

Lead Sponsor: Peking University

Target Recruit Count: 40

Registration Number: NCT05165407

Locations: 🇨🇳
Bejing cancer hospital, Beijing, Beijing, China
🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China

Surufatinib in Patients With Osteosarcoma and Soft Tissue Sarcoma

Phase 2

Recruiting

Conditions: Sarcoma

Interventions: Drug: Surufatinib

First Posted Date: 2021-11-04

Last Posted Date: 2023-04-12

Lead Sponsor: Sun Yat-sen University

Target Recruit Count: 47

Registration Number: NCT05106777

Locations: 🇨🇳
Sun Yat-Sen Univerisity, Guangzhou, Guangdong, China

Open-label Study of Surufatinib in Japanese Patients

Phase 1

Active, not recruiting

Conditions: Neuroendocrine Tumors
Non-hematologic Malignancy

Interventions: Drug: Surufatinib

First Posted Date: 2021-10-14

Last Posted Date: 2024-05-24

Lead Sponsor: Hutchmed

Target Recruit Count: 36

Registration Number: NCT05077384

Locations: 🇯🇵
Kagawa University Hospital, Kagawa, Japan
🇯🇵
Tohoku University Hospital, Sendai, Japan
🇯🇵
Kyushu University Hospital, Fukuoka, Japan

and more 9 locations

A Real-world Study of the Safety and Efficacy of Surufatinib in the Treatment of Biliary Tract Carcinoma

Conditions: Biliary Tract Carcinoma

Interventions: Drug: Surufatinib

First Posted Date: 2021-10-01

Last Posted Date: 2021-10-01

Lead Sponsor: Qilu Hospital of Shandong University

Target Recruit Count: 200

Registration Number: NCT05064852

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy